Active	Status	Sponsor type	Region	Phase	Filter
8 Active 8 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GINESTE, Paul
NCT03368118 / 2017-003284-35: Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis	Active, not recruiting	2a	22	Europe	ABX464	Abivax S.A., Orion Corporation, Orion Pharma	Ulcerative Colitis	03/19	10/22
Vermeire, Severine
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
ReMiDy, NCT04883840: Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis	Recruiting	2/3	220	Europe	Rosuvastatin 10mg	Universitaire Ziekenhuizen KU Leuven, Vlaams Instituut Biotechnologie (VIB)	Ulcerative Colitis	11/25	12/25
NCT04023396 / 2019-000733-39: Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis	Active, not recruiting	2b	217	Europe, Canada, RoW	ABX464	Abivax S.A.	Ulcerative Colitis	12/22	03/23
ABX464-108, NCT05177835 / 2021-004398-30: Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis	Active, not recruiting	2	203	Europe, RoW	ABX464	Abivax S.A., Abivax, ABIVAX	Ulcerative Colitis	02/27	04/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease	Recruiting	2	268	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Crohn's Disease	09/26	07/27